An interventional study of Computerized speed-based cognitive training and Computerized executive function cognitive training in Mild Cognitive Impairment, sponsored by Posit Science Corporation. Recruiting at 1 site in Canada. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by Posit Science Corporation · Not applicable, Interventional, and Treatment
Among 223 studies in Cognitive Dysfunction with a site in Canada — 60 open to participants now, 79 under way, 7 of them phase 3. Cognitive Dysfunction · Canada.
Among the 223 studies in Cognitive Dysfunction with a site in Canada, this one is the 73rd largest by planned enrollment of the 170 interventional ones that give a count, is one of 10 that started in 2026, is one of 115 with no phase, reaches primary completion later than 46 of the 78 other live ones, and was the 217th registered.
3,872 studies on the registry are indexed under Cognitive Dysfunction; 1,119 are open to participants now.
Browse Cognitive Dysfunction studies →60 of the 223 studies in Cognitive Dysfunction with a site in Canada are open now. Recruiting first, the newest first:
Laval University · Sites in Canada
Qanatpharma AG · Sites in Canada
University of British Columbia · Sites in Canada
Ottawa Hospital Research Institute · Sites in Canada
Western University, Canada · Sites in Canada
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 750 Cognitive Dysfunction studies recruiting now, 362 (48%) set no upper age limit and 143 (19%) stop at 75 or younger; 46 take children under 18; 259 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
223 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 29 · Phase 3 21 · Phase 4 3
First in 1999; this study’s year is marked. 10 started in 2026.
This study's planned enrollment of 84 is above the median of 64 across 2,794 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 62 across the 170 interventional studies, 353 across the 52 observational. Of the 121 that completed or were terminated, 17 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 223 have an industry lead sponsor. The 10 most frequent:
Posit Science Corporation is the lead sponsor of 36 studies on the registry; 1 is open to participants now.
Posit Science Corporation has 7 studies filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
24 of the studies in Cognitive Dysfunction with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05230758Phase 3Donald MabbottEffect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour | 2027-11-30 |
| NCT06529744University Health Network, TorontoImproving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling | 2026-11 |
| NCT04335994Sunnybrook Health Sciences CentreENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing | 2026-12 |
| NCT06783283Centre for Addiction and Mental HealthTACS to Engage Theta-Gamma Coupling and Enhance Working Memory in Patients With MCI (tACS-MCI) | 2026-12 |
Among the 223 studies in Cognitive Dysfunction with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a validation study to evaluate efficacy of two neuroplasticity-based, computerized cognitive training programs to improve neurological and neuropsychological health in older adults with mild cognitive impairment (MCI).
The primary objective of this study is to evaluate will evaluate the impact of speed training to change cholinergic signaling, cognitive performance, and functional abilities in patients with MCI, as evidenced by [18F]fluoroethoxybenzovesamicol (FEOBV) positron-emission tomography (PET) and standard measures of cognition and function.
The investigators will employ a prospective, double-blind, parallel-arm, active-controlled, randomized clinical trial in patients with clinically-defined mild cognitive impairment aged 65 and above with a baseline MoCA of 18-26 inclusive.
Approximately 84 participants will be consented to ensure the successful completion of at least 70 participants (post 20% attrition). Participants will then complete the Screening (V0) assessments to determine eligibility. Following inclusion, participants will complete the Baseline (V1) assessments, PET imaging and structural MRI scan; participants will then be randomized into either the speed-based brain training or an active control of visual non-speeded computerized games and will engage in approximately 35 hours of program use for the 10-week Intervention Period. Following the 10-week intervention, participants will complete a Post-Intervention (V2) assessment, and PET imaging to evaluate changes in cognitive function. Participants will then stop using their assigned program for 3 months and return for a Follow-up (V3) end-of-study assessment and PET imaging to evaluate the endurance of changes in cognition, function, and behavior in the absence of further program use.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Potential participant must have MCI as defined by:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Computerized speed-based cognitive training requiring a total maximum of 70 treatment sessions, up to 7 sessions per week, 30 minutes per session.
Other: Computerized speed-based cognitive training
Computerized executive function cognitive training requiring a total maximum of 70 treatment sessions, up to 7 sessions per week, 30 minutes per session.
Other: Computerized executive function cognitive training
Thirty minutes of training on computerized exercises that targets visual processing speed, memory, attention and alertness.
Thirty minutes of training on computerized exercises that target executive function.
Change in Global cholinergic signaling using [18F]fluoroethoxybenzovesamicol (FEOBV) positron-emission tomography (PET)
FEOBV standard uptake value ratios (SUVR) in the global cortex ROI. Higher score is better.
Time frame: at 3 months (post-intervention)
Change in Memory-based cholinergic signaling in hippocampus gyrus using [18F]fluoroethoxybenzovesamicol (FEOBV) positron-emission tomography (PET)
FEOBV-PET standard uptake value ratios (SUVR) hippocampus gyrus using Matched MNI-space region via Hammers Atlas. Higher score is better.
Time frame: at 3 months (post-intervention)
Change in Memory-based cholinergic signaling in parahippocampal gyrus using [18F]fluoroethoxybenzovesamicol (FEOBV) positron-emission tomography (PET)
FEOBV-PET standard uptake value ratios (SUVR) parahippocampal gyrus using Matched MNI-space region via Hammers Atlas. Higher score is better
Time frame: at 3 months (post-intervention)
Change in NIH EXAMINER Executive Composite Score
The NIH EXAMINER is a computer based battery of executive function tests which yields a total or 'composite' score to represent global executive functioning. Higher score is better.
Time frame: at 3 months (post-intervention) and at 6 months (follow-up)
Change in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score
The Clinical Dementia Rating (CDR) Scale is a validated assessment for evaluating severity of dementia. Lower score is better.
Time frame: at 3 months (post-intervention) and at 6 months (follow-up)
Change in Double Decision train-to-task Assessment Score
This is a computerized assessment that serves as a positive control for task learning. A single exposure duration (in milliseconds) required for users to achieve approximately 80% criterion accuracy in identification of central and peripheral targets. Higher score is better.
Time frame: at 3 months (post-intervention) and at 6 months (follow-up)
Change in Eye-tracking Test
Eye movements will be measured to determine acetylcholinergic function over time. A series of oculomotor tasks will be presented sequentially on an iPad Pro for approximately 20 minutes. Each task consists of visual stimuli designed to elicit specific eye movements. The iPad's front-facing camera will record facial and eye movements during task performance.
Time frame: at 3 months (post-intervention) and at 6 months (follow-up)
Start is estimated for Sep 2026; primary completion for May 2027, 8 months later.
Of 69 industry-sponsored interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's planned 8 months is below that.
Counting every sponsor, half of 1,511 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.